Literature DB >> 2657323

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

R A DeFronzo1, E Ferrannini, D C Simonson.   

Abstract

The factors responsible for fasting hyperglycemia were investigated in 77 normal weight non-insulin-dependent diabetic (NIDD) and 72 age-, sex-, and weight-matched control individuals. In diabetic subjects with mild fasting hyperglycemia (less than 140 mg/dL) hepatic glucose production (1.85 +/- 0.03 mg/kg.min) was similar to controls (1.84 +/- 0.02); the major factor responsible for the elevated basal glucose level in the diabetic group was a decreased efficiency in the tissue uptake of glucose, as reflected by a 30% decline in the rate of glucose clearance (1.56 +/- 0.03 v 2.00 +/- 0.03 mL/kg.min, P less than .001). In contrast, in diabetic subjects with fasting plasma glucose concentrations above 140 mg/dL, basal hepatic glucose production was significantly elevated (2.42 +/- 0.08 mg/kg.min, P less than .001) and correlated closely with the increase in fasting plasma glucose concentration (r = .796, P less than .001). The basal rate of whole body glucose clearance reached a plateau value at fasting glucose levels of 160 to 180 mg/dL and did not contribute to the further rise in fasting plasma glucose concentrations above 160 to 180 mg/dL. Decreased efficiency of tissue glucose uptake is responsible the development of fasting hyperglycemia in patients with mild NIDDM (fasting plasma glucose less than 140 mg/dL). As the diabetic state worsens, an increase in basal hepatic glucose production is the major factor responsible for the progressive rise in fasting glucose levels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2657323     DOI: 10.1016/0026-0495(89)90129-7

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  118 in total

1.  Pathogenesis of type 2 diabetes: implications for metformin.

Authors:  R A DeFronzo
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 2.  Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview.

Authors:  R A DeFronzo
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

3.  A novel surrogate index for hepatic insulin resistance.

Authors:  J Vangipurapu; A Stančáková; T Kuulasmaa; J Paananen; J Kuusisto; E Ferrannini; M Laakso
Journal:  Diabetologia       Date:  2010-11-25       Impact factor: 10.122

4.  Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.

Authors:  Yan-Ling He; Jessica Valencia; Yiming Zhang; Sherwyn L Schwartz; Monica Ligueros-Saylan; James Foley; William P Dole
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

5.  Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals.

Authors:  A Avogaro; G Toffolo; M Miola; A Valerio; A Tiengo; C Cobelli; S Del Prato
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 6.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

7.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Authors:  E Bugianesi; A Gastaldelli; E Vanni; R Gambino; M Cassader; S Baldi; V Ponti; G Pagano; E Ferrannini; M Rizzetto
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

8.  Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning.

Authors:  Ram Weiss; Sylvie Dufour; Sara E Taksali; William V Tamborlane; Kitt F Petersen; Riccardo C Bonadonna; Linda Boselli; Gina Barbetta; Karin Allen; Francis Rife; Mary Savoye; James Dziura; Robert Sherwin; Gerald I Shulman; Sonia Caprio
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

Review 9.  Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.

Authors:  Ralph A DeFronzo
Journal:  Diabetes Obes Metab       Date:  2017-06-07       Impact factor: 6.577

Review 10.  Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes.

Authors:  Ashot Sargsyan; Mark A Herman
Journal:  Curr Diab Rep       Date:  2019-08-03       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.